We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 28

China’s comprehensive health care reform plan: implications for pharmaceutical and device firms

  • Sidley Austin LLP
  • -
  • China
  • -
  • April 9 2009

On April 6, the State Council of China made public the Guideline on Further Reforming the Health Care System (the Guideline), and on the following day the Action Plan for Health Care System Reform: 2009 - 2011 (the Action Plan

China issues new rule on medical device advertisements

  • Sidley Austin LLP
  • -
  • China
  • -
  • June 5 2009

On May 13, the Ministry of Health (MOH), the State Administration of Industry and Commerce (SAIC) and the State Food and Drug Administration (SFDA) of China jointly issued an amended Rule for Review of Medical Device Advertisements (the Rule) and accompanying Standards for Review of Medical Device Advertisements (the Standards), both of which went into effect on May 20

China proposes new ADR reporting rule

  • Sidley Austin LLP
  • -
  • China
  • -
  • July 30 2009

On June 30, the Ministry of Health ("MOH") and the State Food and Drug Administration ("SFDA") of China issued a draft revision of the Rule on Adverse Drug Reaction Reporting and Monitoring (the "Reporting Rule"

New PRC Tort Law offers clarification on medical product liability, remains silent on top industry concerns

  • Sidley Austin LLP
  • -
  • China
  • -
  • January 29 2010

After eight years of deliberation and four rounds of revisions, the Tort Law of the People's Republic of China (the Tort Law) was adopted by the Standing Committee of the National People's Congress on December 26, 2009 and will become effective on July 1, 2010

China proposes new drug GMPs, significantly raising standards

  • Sidley Austin LLP
  • -
  • China
  • -
  • October 28 2009

On September 23, the State Food and Drug Administration of China ("SFDA") published a draft of revised drug good manufacturing practices ("GMP") for public comments ("GMP 2009"

SFDA’s working plan for the year of tiger

  • Sidley Austin LLP
  • -
  • China
  • -
  • February 16 2010

On January 19, 2010, officials from the State Food and Drug Administration (SFDA) and its local counterparts gathered together in Beijing to attend the 2010 National Conference on the Food and Drug Administration

China heightens crackdown on commercial bribery in pharmaceutical industry

  • Sidley Austin LLP
  • -
  • China
  • -
  • July 7 2010

On June 21, 2010, the Ministry of Health of China (MOH) published a notice in which it identifies key measures that local health authorities are required to take to crack down on commercial bribery in the pharmaceutical industry (the “Notice”

Commercial bribery enforcement in the healthcare industry: what’s next?

  • Sidley Austin LLP
  • -
  • China
  • -
  • January 19 2011

In 2010,we witnessed an increasing number of enforcement actions taken by the local Administrations for Industry and Commerce ("AIC") in China against sales and promotional activities undertaken by healthcare companies, alleging commercial bribery

China’s new drug GMP significantly raises drug manufacturing standards

  • Sidley Austin LLP
  • -
  • China
  • -
  • February 17 2011

On February 12, 2011, after rounds of revisions that took more than 5 years, the Ministry of Health of China ("MOH") published the final version of China's new drug GMP ("GMP 2010"

Drug pricing reform: an opportunity and challenge

  • Sidley Austin LLP
  • -
  • China
  • -
  • March 25 2011

The Chinese National Development and Drug Commission ("NDRC"), the authority in charge of drug pricing, recently slashed the maximum retail price of 162 cardiovascular and anti-infective drug products by an average of 21